Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs (BLOOD Trial)

NCT04473027 is registered in ClinicalTrials.gov with University Hospital, Ghent as lead sponsor.

NCT NCT04473027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04473027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BLood Groups as Biomarker to Optimize Odds of Response to Anti-PD-1 Drugs (BLOOD Trial)
Lead sponsor
University Hospital, Ghent
Phase
Observational
Overall status
Terminated
Start date
September 1, 2020
Completion date
April 22, 2021
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, melanoma